Related Experiment Video
Updated: May 5, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.6K
Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes
Adam D Timmis1, Bernard R Chaitman, Michael Crager
1Department of Cardiology, London Chest Hospital, Bonner Road, London E2 9JX, UK. timmis@1ch.demon.co.uk
European Heart Journal
|September 24, 2005
Summary
Ranolazine effectively treated angina in both diabetic and non-diabetic patients, demonstrating similar safety and efficacy. This anti-anginal medication also significantly improved glycemic control in patients with diabetes.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Stable angina affects both diabetic and non-diabetic individuals.
- Assessing ranolazine's efficacy and safety in these distinct patient groups is crucial.
- Glycemic control is a key consideration in diabetic patients with cardiovascular conditions.
Purpose of the Study:
- To evaluate the anti-anginal efficacy and safety of ranolazine in diabetic versus non-diabetic patients.
- To assess the impact of ranolazine on glycemic control in diabetic patients.
- To analyze ranolazine's effects within the context of the Combination Assessment of Ranolazine In Stable Angina (CARISA) trial.
Main Methods:
- Patients with chronic angina were randomized to placebo or ranolazine (750 or 1000 mg twice daily) for 12 weeks.
- Exercise tolerance, angina frequency, nitroglycerin use, glucose, HbA1c, and lipids were measured.
- Diabetic and non-diabetic patients were compared, with an open-label extension study for long-term assessment.
Main Results:
- Ranolazine demonstrated similar improvements in exercise parameters, angina frequency, and nitroglycerin use in both diabetic and non-diabetic patients.
- Adverse events were comparable between the groups.
- A post hoc analysis revealed significant reductions in HbA1c levels in diabetic patients treated with ranolazine compared to placebo.
Conclusions:
- Ranolazine is similarly effective and safe for managing angina in both diabetic and non-diabetic patients.
- Ranolazine offers a significant benefit in improving glycemic control for diabetic patients.
- These findings support ranolazine as a therapeutic option for stable angina, with added glycemic benefits for diabetic individuals.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:22Heart Failure Drugs: β-Blockers
2.9K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.9K
01:16Antianginal Drugs: Nitrates and β-Blockers
1.9K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
01:20Angina V: Nursing Management
567
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
567
01:30Heart Failure V: Medical Management
641
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
641